Are Medical Stocks Lagging McKesson (MCK) This Year?

McKesson (MCK) has notably outperformed its peers and the broader Medical sector year-to-date, posting a 23.9% gain compared to the sector's 3.5% average loss and its specific Medical - Dental Supplies industry's 0.8% gain. This strong performance is supported by a Zacks Rank #2 (Buy) and a 1.8% increase in its full-year earnings consensus estimate. Similarly, Cencora (COR), also a Zacks Rank #2 (Buy), has returned 27.4% YTD, significantly outpacing its declining Medical Services industry, indicating both companies are robust individual performers within a challenging broader medical market.

Analysis

McKesson (MCK) is demonstrating significant relative strength, with its stock gaining 23.9% year-to-date, in stark contrast to the broader Medical sector's average loss of 3.5%. This outperformance extends to its specific industry, Medical - Dental Supplies, which has seen a marginal gain of 0.8%. The positive momentum is underpinned by improving fundamentals, evidenced by a Zacks Rank of #2 (Buy) and a 1.8% upward revision in its full-year consensus earnings estimate over the past quarter. This suggests strengthening analyst sentiment and a positive earnings outlook. Similarly, Cencora (COR) has also shown robust performance with a 27.4% year-to-date return, substantially exceeding its Medical Services industry, which has declined by 6.3%. Cencora shares a similar profile to McKesson, with a Zacks Rank #2 (Buy) and a 2.5% increase in its consensus EPS estimate. The key takeaway is a clear divergence where specific companies with strong, improving earnings outlooks are bucking negative trends prevalent within their respective industries and the wider medical sector.

Key Decisions for Investors

• Investors seeking exposure to the medical space should consider overweighting positions in McKesson and Cencora, as they are demonstrating significant outperformance and positive estimate revisions while their respective sectors lag.
• The bullish thesis for both MCK and COR is heavily tied to their improving earnings outlooks; therefore, closely monitor future consensus estimate revisions for any signs of deceleration or reversal.
• Given the underperformance of the broader Medical sector (-3.5%) and the Medical Services industry (-6.3%), investors should remain aware of potential sector-wide headwinds that could eventually impact these leading stocks, despite their current momentum.